Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678893 | 0.84 | GPBAR1 (0.39) | GPBAR1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL6682018 | 0.82 | KMT2A (0.39) | GPBAR1MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL6716879 | 0.71 | CNR2 (0.43) | KMT2AALDH1A1HTR7KDM4ESMN1; SMN2 | |
| SCHEMBL7005686 | 0.66 | ALDH1A1 (0.44) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL17251633 | 0.63 | TDP1 (0.49) | GPBAR1KMT2AALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL8133573 | 0.61 | CASP3 (0.57) | MEN1KMT2AALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL21659487 | 0.61 | TDP1 (0.56) | GPBAR1KMT2AALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL663552 | 0.61 | KMT2A (0.76) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL21869796 | 0.60 | P2RX7 (0.54) | MEN1KMT2AALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL28650737 | 0.60 | P2RX7 (0.54) | MEN1KMT2AALDH1A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034009-A1 | 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP11 | GPBAR1 3055/4885MEN1 3416/4885KMT2A 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.